SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), Clearmind filed three patent applications under the international Patent Cooperation Treaty. The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine and Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide. “We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset,” said SciSparc’s Chief Executive Officer, Oz Adler. “We believe in the added value that CannAmide can offer when combined with various psychedelic compounds that are known for their therapeutics advantages.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SPRC:
- SciSparc initiates patient recruitment for clinical trial with SCI-210
- SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
- SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
- SciSparc announces $20M standby equity purchase agreement
- SciSparc enters into bridge loan agreement with vehicle importer in Israel